Non-Conventional Radiotherapy May Reduce Dry Mouth
Parotid-sparing intensity-modulated radiotherapy (IMRT) is less likely than conventional radiotherapy to result in dry mouth in patients treated for head and neck cancer, according to research published online Jan. 13 in The Lancet Oncology.
THURSDAY, Jan. 13 (HealthDay News) -- Parotid-sparing intensity-modulated radiotherapy (IMRT) is less likely than conventional radiotherapy to result in dry mouth in patients treated for head and neck cancer, according to research published online Jan. 13 in The Lancet Oncology.
Christopher M. Nutting, M.D., of the Royal Marsden Hospitals NHS Foundation Trust in London, and colleagues randomized 94 patients with pharyngeal squamous-cell carcinoma to IMRT or conventional radiotherapy to test their hypothesis that IMRT reduces the incidence of severe xerostomia.
The researchers found that, of the patients available for analysis at 12 months, 38 percent of those in the IMRT group reported grade 2 or worse xerostomia, compared with 74 percent of the conventional radiotherapy group. By 24 months, 29 percent of the IMRT group and 83 percent of the conventional radiotherapy group reported grade 2 or worse xerostomia. The IMRT group had a higher prevalence of grade 2 or worse fatigue, but there were no significant differences between the two groups in terms of non-xerostomia late toxicities, locoregional control, or overall survival.
"Sparing the parotid glands with IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck," the authors write.
AbstractFull Text (subscription or payment may be required)
Copyright © 2011 HealthDay. All rights reserved.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
